Submitted by: Submitted by Shashiipawar
Views: 10
Words: 552
Pages: 3
Category: Business and Industry
Date Submitted: 11/22/2016 04:56 AM
Major Depressive Disorder (MDD) is one of the most common mental disorder characterized by persistent and tenacious low mood that interferes with the person’s ability to work, eat, sleep and normal activities. MDD is also referred as clinical depression, major depression, and unipolar depression or as recurrent depression. The common symptoms associated with this disorder include insomnia, loss of interest, recurrent thoughts of death, feelings of worthlessness and reduced ability to think. Increasing number of patients suffering from MDD has grabbed the attention of MDD drugs manufacturer to invest into MDD treatment market.
Major Depressive Disorder (MDD) Treatment Market: Drivers and Restraints
Work life imbalances due to change in life style, and increase in MDD patient pool are the key drivers expected to drive the MDD treatment market over the forecasted period. Partnerships for co-development and co-marketing of MDD drugs among the drug manufactures across the globe, development of new drugs, and adequate government reimbursement policies have also fueled the growth of MDD treatment market. However, stringent regulations imposed by various governments for new drug approval, patent expiries of some blockbuster drugs, risk of complications with other medications, and related side effects of MDD drugs may hinder the growth of MDD treatment market over the forecasted period.
Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1314
Major Depressive Disorder (MDD) Treatment Market: Segmentation
The global MDD treatment market is segmented based on drug type used for the treatment of MDD.
Antidepressants
Selective Serotonin Reuptake Inhibitors (Ssris)
Dopamine Norepinephrine Reuptake Inhibitor
Serotonin Norepinephrine Reuptake Inhibitor
Serotonin Modulators
Norepinephrine-Serotonin Modulator
Tricyclics and Tetracyclics
Monoamine Oxidase Inhibitors (MAOIs)
Irreversible, non-selective inhibitors
Phenelzine...